Furagin Derivatives—Nitrofuran‐Based Hydrazones as Potential Dual Inhibitors of Thioredoxin Reductase and Carbonic Anhydrases
ChemMedChem · 14.07.2026 · 21 (13)
DOI: 10.1002/cmdc.70379 ↗Kurz gefasst
Fachartikel in der Zeitschrift ChemMedChem, online erschienen am 08.07.2026. Verfasst von Aleksandrs Pustenko und 6 weiteren Autor:innen. Beteiligte Einrichtung: Latvian Institute of Organic Synthesis, Riga, Latvia. Hauptthemen laut MEDLINE: Hydrazones, Thioredoxin-Disulfide Reductase, Carbonic Anhydrase Inhibitors, Carbonic Anhydrases. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Recovery and Resilience Facility (RRF).
Abstract (Originalsprache)
Cancer remains one of the leading causes of mortality, accounting for millions of deaths worldwide each year and posing a persistent challenge to global health despite advances in diagnosis and treatment. Dual inhibition of thioredoxin reductase (TrxR) and cancer‐associated carbonic anhydrase (CA) isoforms IX and XII represents a promising strategy for selective anticancer therapy by simultaneously disrupting cellular redox homeostasis and pH regulation. The antibacterial agent furagin has been previously explored as an inhibitor of cancer‐associated carbonic anhydrases; however, its potential as a TrxR inhibitor has not yet been investigated. In this study, a series of furagin derivatives—nitrofuran‐based hydrazones ( 7a – 7s )—were designed and synthesized as potential dual TrxR/CA inhibitors. The derivatives were screened for CA inhibition using a stopped‐flow CO 2 hydration assay and for rTrxR1 inhibition via a 5,5′‐Dithiobis(2‐nitrobenzoic acid) (DTNB) reduction assay. Most derivatives displayed weak or negligible activity against the cytosolic isoforms hCA I and hCA II while exhibiting moderate and selective inhibition of the cancer‐associated isoforms hCA IX and hCA XII, particularly hCA XII. Several compounds also inhibited rTrxR1, with compound 7g emerging as the most potent inhibitor in the series (IC 50 = 11 μM).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Latvian Institute of Organic Synthesis, Riga, Latvia.
- The National Institute of Research and Innovation (NIRI), Riga, Latvia.
- Baltic Biomaterials Centre of Excellence, Headquarters at Riga Technical University, Riga, Latvia.
- Department of Neurofarba, Università degli Studi di Firenze, Florence, Italy.
- Institute of Chemistry and Chemical Technology, Faculty of Natural Sciences and Technology, Riga Technical University, Riga, Latvia.
ORCID-Profile: Aleksandrs Pustenko, Andrea Angeli, Claudiu T Supuran
Förderung
- Recovery and Resilience Facility (RRF)
Zitieren
APA
Pustenko, A., Bobrovs, R., Freimane, K., Sizovs, A., Angeli, A., Supuran, C. T., & Žalubovskis, R. (2026). Furagin Derivatives—Nitrofuran‐Based Hydrazones as Potential Dual Inhibitors of Thioredoxin Reductase and Carbonic Anhydrases. ChemMedChem, 21(13). https://doi.org/10.1002/cmdc.70379
Vancouver
Pustenko A, Bobrovs R, Freimane K, Sizovs A, Angeli A, Supuran CT, et al. Furagin Derivatives—Nitrofuran‐Based Hydrazones as Potential Dual Inhibitors of Thioredoxin Reductase and Carbonic Anhydrases. ChemMedChem. 2026;21(13). doi:10.1002/cmdc.70379
BibTeX
@article{Pustenko2026,
author = {Pustenko, Aleksandrs and Bobrovs, Raitis and Freimane, Katrīna and Sizovs, Antons and Angeli, Andrea and Supuran, Claudiu T and Žalubovskis, Raivis},
title = {Furagin Derivatives—Nitrofuran‐Based Hydrazones as Potential Dual Inhibitors of Thioredoxin Reductase and Carbonic Anhydrases},
journal = {ChemMedChem},
year = {2026},
volume = {21},
number = {13},
doi = {10.1002/cmdc.70379}
}
EUVIMED